Therefore, pharmacological inhibitions of the TKI-insensitive EGFR signaling and the EGFR C797S by reducing EGFR protein expression may offer therapeutic opportunities for NSCLC patients with acquired TKI resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.